All In Biotech

Drug Trial Radar · NCT07929350

Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Therapy

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Jan 15, 2028

Study completion Mar 15, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial tests whether Fuling Yunhua Granules and Dihuang Baoyuan Granules, given in sequence with or without continued metformin, lower blood sugar in adults with type 2 diabetes already taking metformin. It will also assess their safety.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Fuling Yunhua GranulesDrug

    Traditional Chinese herbal medicine granules, 12 g per bag, taken orally before meals.

  • Dihuang Baoyuan GranulesDrug

    Traditional Chinese herbal medicine granules, 18 g per bag, taken orally before meals.

  • Fuling Yunhua Granules Matched PlaceboDrug

    Matched placebo for Fuling Yunhua Granules; identical in appearance (shape, color and packaging), odor and taste, but containing no active herbal components. Granules, 12 g per bag, taken orally before meals.

  • Dihuang Baoyuan Granules Matched PlaceboDrug

    Matched placebo for Dihuang Baoyuan Granules; identical in appearance (shape, color and packaging), odor and taste, but containing no active herbal components. Granules, 18 g per bag, taken orally before meals.

  • MetforminDrug

    Oral biguanide antihyperglycemic agent, 0.5 g per tablet, taken orally as stable background therapy throughout the study.

  • Metformin Matched PlaceboDrug

    Matched placebo for metformin; identical in appearance (shape, color and packaging) to metformin tablets, but containing no active pharmaceutical ingredients. Tablets, 0.5 g per tablet, taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Glycated Hemoglobin (HbA1c) at Week 24Time frame: Baseline and Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.